Certara Reports Modest Revenue Growth but Significant Losses in Q2 2026

Certara, Inc. reported its financial results for the second quarter and first half of 2026, revealing a modest increase in revenue but significant losses attributed to operational challenges and a recent divestiture. For the three months ended June 30, 2026, the company generated revenues of $93.3 million, a 1% increase from $92.4 million in the same period of 2025. For the first half of 2026, total revenues reached $187.4 million, up 2% from $184.5 million year-over-year. However, the company recorded a net loss of $55.3 million for the quarter, compared to a loss of $2.0 million in the prior year, and a net loss of $64.0 million for the first half, down from a profit of $2.8 million in 2025.

The financial performance was impacted by a significant increase in operating expenses, which rose to $124.0 million for the first half of 2026, compared to $103.5 million in the same period of 2025. This increase was primarily driven by a $13.1 million rise in business acquisition contingent consideration expenses and a $5.2 million increase in general and administrative costs. The company also reported a notable increase in sales and marketing expenses, which grew by 7% to $27.9 million for the first half of 2026, reflecting ongoing investments in customer acquisition and retention.

In a strategic move, Certara completed the sale of its Regulatory and Medical Writing business to Veristat, LLC on May 8, 2026, for $69.4 million, with an additional $15 million held in escrow. This divestiture is part of the company's strategy to streamline operations and focus on its core biosimulation services. The transaction resulted in a pre-tax loss of $65.5 million, which significantly contributed to the overall net loss reported for the quarter. The company has classified the results of this business as discontinued operations in its financial statements.

Operationally, Certara reported a customer base of over 160,000 users for its software products, with services utilized by more than 2,600 life sciences companies and academic institutions. The company continues to expand its geographic footprint, with operations in multiple countries including the U.S., Canada, and several European and Asian nations. Despite the challenges faced, Certara remains committed to investing in research and development, particularly in integrating artificial intelligence into its offerings, which it believes will enhance its competitive position in the market.

Looking ahead, Certara anticipates continued revenue growth driven by its software products and services, although it acknowledges the potential for fluctuations in bookings and net retention rates due to market conditions. The company plans to maintain its focus on innovation and customer engagement to navigate the evolving landscape of the biopharmaceutical industry.